Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the European Renal Association ...Middle East

EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including IgA nephropathy (IgAN), minimal change disease (MCD), focal segmental glomerulosclerosis...

Read More Details
Finally We wish PressBee provided you with enough information of ( Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the European Renal Association )

Also on site :

• Israel strikes Syria again, claims to have killed alleged Hamas member
• 'Full House' Star, 43, Makes Rare Comment About Ashley Olsen
• '90s Rapper and Actor, 61, Makes Rare Red Carpet Appearance